All illnesses arise at least in part from abnormal communications – or signaling – within and between the cells that make up the human body. Abnormal signaling leads to imbalances in how the body functions. Resonant molecular signaling (RMS) is a novel drug development platform that aims to address a wide range of illnesses by restoring normal cellular communications and correcting these imbalances.

Administered in micro-dose quantities, RMS therapies act as signals to induce a cascade of events that results in up-or-down regulation of genes that are involved in complex protein pathways to affect the disturbed homeostasis of diseased tissues or cells.

Functioning as a part of normal cellular signaling machinery, employing the RMS approach avoids the sledgehammer-like outcomes associated with the use of receptor agonists or antagonist small molecule therapeutics.

More than two decades of research with clinicians and leading medical institutions has established the foundational characteristics of RMS therapies:

  • They often positively influence seemingly unrelated medical conditions.
  • Their effects are generally quick and reproducible in large numbers of patients.
  • Doses are independent of age or weight of patient.
  • Effective delivery methods include: sublingual drop, subcutaneous injections, oral formulations and transdermal cream.
  • They can be used in conjunction with conventional medicines or as standalone treatments.

Validation of RMS Technology occurs through formal clinical trials and peer-reviewed publications.